Last reviewed · How we verify
SHR7280；Ganirelix Acetate Injection simulant
Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion.
Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. Used for Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.
At a glance
| Generic name | SHR7280；Ganirelix Acetate Injection simulant |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | GnRH antagonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive/Fertility |
| Phase | Phase 3 |
Mechanism of action
Ganirelix competitively blocks GnRH receptors in the pituitary gland, rapidly inhibiting gonadotropin release without an initial flare effect. This suppression of LH and FSH is used to prevent premature ovulation during controlled ovarian hyperstimulation in assisted reproductive technology cycles.
Approved indications
- Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology
Common side effects
- Injection site reactions
- Headache
- Abdominal pain
- Nausea
- Ovarian hyperstimulation syndrome
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: